secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001193125-26-193927
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo appoints Dr. Laura Sepp-Lorenzino to board and Science & Technology Committee
--------------------------------------------------------------------------------

- Dr. Sepp-Lorenzino appointed April 28, 2026; term expires at 2028 annual meeting.
- She joins Science & Technology Committee; prior CSO of Intellia Therapeutics (2019-2025).
- Compensation: $40k annual cash, initial option for 50,000 shares; first annual grant in 2027.
- Previously held leadership roles at Vertex, Alnylam, and Merck in RNA therapeutics/oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526193927/0001193125-26-193927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526193927/lxeo-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-193927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer